You are here: Home » News-CM » Companies » News
Business Standard

Zydus receives final approval for Diltiazem Hydrochloride Extended-Release Capsules

Capital Market 

From USFDA

Zydus Cadila has received the final approval from the USFDA to market Diltiazem Hydrochloride Extended-Release Capsules USP in strengths of 120 mg, 180 mg, 240 mg, 300 mg and 360 mg. The drug is used in the treatment of hypertension (high blood pressure), angina (chest pain) and certain heart rhythm disorders. It will produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, August 09 2017. 11:42 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU